STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1068 by analyst upside · 2026-08-12
ACH
Accendra Health, Inc.
Healthcare · Market Cap $97M · P/E 0x
ANALYST PRICE TARGET
+67.5%
implied upside to consensus target
Current Price $1.26
Consensus Target $2.11
Bull Target $4.5
Bear Target $1.3
Analysts Covering 5
ANALYST CONSENSUS - UNDERPERFORM
Strong Buy
0
Buy
0
Hold
3
Sell
2
52-Week Low $1.2
52-Week High $5.85
YTD Return -45.7%
FUNDAMENTALS
Market Cap $97M
P/E Ratio (TTM) N/A
Forward P/E 2.2x
EPS (TTM) $-1.37
PEG Ratio 0.70
Dividend Yield N/A
Revenue (TTM) $2.6B
Profit Margin -11.4%
52-WEEK RANGE
52-Week Low $1.2
52-Week High $5.85
Current Price $1.26
Bear Target $1.3
Bull Target $4.5
● Now $1.26 ● Target $2.11
TRADING DATA
Avg Volume 873K
YTD Return -45.7%
Analyst Count 5
Consensus Underperform
Upside to Target +67.5%
Last Updated 2026-08-12

ANALYST SUMMARY

Accendra Health, Inc. (ACH) is currently trading at $1.26 with a Wall Street consensus price target of $2.11, implying potential upside of 67.5% over the next 12 months. 5 analysts currently cover ACH, with a consensus rating of Underperform - 0% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $4.5, while the most cautious has a target of $1.3.

ACH operates in the Healthcare sector with a market capitalisation of $97M. The stock is down 45.7% year-to-date and is currently trading near the lower end of its 52-week range of $1.2 – $5.85.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ACH, with each firm's 90-day track record across all stocks we track. See full firm rankings →

UBS - Reiterated
Neutral → Neutral 2026-05-12 33% win rate (6 calls)
Citigroup - Reiterated
Buy → Buy 2026-05-12 Building track record
Baird - Reiterated
Outperform → Outperform 2026-05-12 Building track record
Leerink Partners - Reiterated
Market Perform → Market Perform 2026-02-20 29% win rate (7 calls)
Citigroup - Reiterated
Buy → Buy 2026-01-09 Building track record
UBS ↓ Downgrade
Buy → Neutral 2025-11-03 33% win rate (6 calls)
JP Morgan - Reiterated
Underweight → Underweight 2025-08-27 43% win rate (7 calls)
UBS - Reiterated
Buy → Buy 2025-08-13 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
16
out of 100
Coverage depth
14/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →